These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. van der Wal PS, Draeger KE, van Iperen AM, Martini C, Aarsen M, Heine RJ. Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393 [Abstract] [Full Text] [Related]
9. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Clark HE, Matthews DR. Horm Metab Res; 1996 Sep 14; 28(9):445-50. PubMed ID: 8911981 [Abstract] [Full Text] [Related]
11. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Goldberg RB, Holvey SM, Schneider J. Diabetes Care; 1996 Aug 14; 19(8):849-56. PubMed ID: 8842603 [Abstract] [Full Text] [Related]
13. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Clin Ther; 2003 Feb 14; 25(2):472-84. PubMed ID: 12749508 [Abstract] [Full Text] [Related]
16. Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes. Hwang YC, Kang M, Ahn CW, Park JS, Baik SH, Chung DJ, Jang HC, Kim KA, Lee IK, Min KW, Nam M, Park TS, Son SM, Sung YA, Woo JT, Park KS, Lee MK. Int J Clin Pract; 2013 Mar 14; 67(3):236-43. PubMed ID: 23336668 [Abstract] [Full Text] [Related]
17. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. Kim BH, Shin KH, Kim J, Lim KS, Kim KP, Kim JR, Cho JY, Shin SG, Jang IJ, Yu KS. Clin Ther; 2009 Nov 14; 31(11):2755-64. PubMed ID: 20110017 [Abstract] [Full Text] [Related]
18. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Østoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, Knop FK, Vilsbøll T. Diabetes Care; 2014 Jul 14; 37(7):1797-805. PubMed ID: 24929431 [Abstract] [Full Text] [Related]
20. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, Maffioli P. Metabolism; 2014 Jul 14; 63(7):957-67. PubMed ID: 24874591 [Abstract] [Full Text] [Related] Page: [Next] [New Search]